US Appeals Court Blocks FDA Rule Allowing Mail-Order Abortion Pills

A US federal appeals court issued a temporary order on Thursday blocking the Food and Drug Administration’s (FDA) rule that allowed women to obtain the abortion drug mifepristone by mail, CNN and The New York Times reported. The ruling will have significant implications for medication abortion accessibility across the country.

The Ruling

The appeals court’s temporary order effectively suspends the FDA’s expanded policy that permitted certified healthcare providers to mail mifepristone to patients. Mifepristone is the primary drug used in medication abortions, which currently represent the most common method for the procedure in the United States.

The ruling is the latest development in an ongoing legal campaign by anti-abortion organizations and state governments challenging the FDA’s regulatory decisions on the drug. Opponents argue that mailing prescription abortion drugs poses safety risks and should be subject to stricter oversight.

Impact

The mifepristone-misoprostol medication abortion regimen is currently the most prevalent method for terminating early pregnancies in the US. The FDA’s previous rule allowing mail distribution of the drug significantly expanded access for women in remote areas and states with restrictive abortion laws.

The temporary order will reintroduce barriers to medication access for this population, particularly in states that have implemented strict abortion restrictions.

Reactions

Pro-choice organizations strongly condemned the ruling, arguing it infringes on personal medical autonomy. Related legal groups have indicated they will continue pursuing legal avenues to defend the FDA’s original policy.

Conversely, anti-abortion groups welcomed the ruling as an interim victory and called on the court to permanently overturn the FDA’s mail distribution rule.

The FDA’s regulatory approach to mifepristone has undergone several changes in recent years. In 2021, the agency eliminated the in-person dispensing requirement, allowing the drug to be distributed by mail. Since then, anti-abortion states and organizations have filed multiple lawsuits seeking to reverse this policy change.

It remains unclear whether the appeals court’s temporary order will persist and how the case will proceed through higher levels of the judicial system.

Source: CNN, The New York Times